QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Q/C TECHNOLOGIES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.50−0.04 (-7.10%)
Close on Oct 19, 2026
- Market cap
- $4.12M
- P/E (TTM)
- –
- Dividend yield
- –
Q/C TECHNOLOGIES, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 20 | Q1 20 | Q4 19 | Q3 19 | Q2 19 | Q1 19 | Q4 18 | Q3 18 | Q2 18 | Q1 18 | Q4 17 | Q2 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue [Member] | – | – | – | – | – | – | $279.41K | $557.09K | $526.60K | – | – | $1.10M | – | – |
| Product Revenue Related Party [Member] | – | – | – | – | – | – | – | – | – | – | – | -$24.06K | – | – |
By region
| Revenue | Q2 20 | Q1 20 | Q4 19 | Q3 19 | Q2 19 | Q1 19 | Q4 18 | Q3 18 | Q2 18 | Q1 18 | Q4 17 | Q2 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | -$1.89K | – | $79.59K | $420.81K | $447.01K | $612.12K | $265.41K | $554.27K | $462.38K | $294.73K | – | – | – | -100.4% |
| Rest of World [Member] | – | – | $0 | $0 | $17.50K | – | $14.00K | $2.82K | $64.22K | $7.74K | – | $82.40K | – | – |
| People's Republic of China [Member] | – | – | – | – | – | – | – | – | – | – | – | $478.21K | – | – |
| United States [Member] | – | – | – | – | – | – | – | $554.27K | $462.38K | $294.73K | – | $512.26K | – | – |
From the segment and revenue-disaggregation notes of Q/C Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.